4//SEC Filing
Vivo Capital Surplus Fund VIII, L.P. 4
Accession 0001213900-20-008792
CIK 0001658247other
Filed
Apr 6, 8:00 PM ET
Accepted
Apr 7, 7:27 PM ET
Size
14.8 KB
Accession
0001213900-20-008792
Insider Transaction Report
Form 4
Vivo Capital VIII, LLC
10% Owner
Transactions
- Sale
Common Stock
2020-04-07$14.20/sh−5,373$76,297→ 2,453,072 total(indirect: See footnotes) - Sale
Common Stock
2020-04-07$14.20/sh−742$10,536→ 338,738 total(indirect: See footnotes) - Sale
Common Stock
2020-04-03$13.80/sh−263,600$3,637,680→ 2,458,445 total(indirect: See footnotes) - Sale
Common Stock
2020-04-03$13.80/sh−36,400$502,320→ 339,480 total(indirect: See footnotes)
Vivo Capital Fund VIII, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-04-03$13.80/sh−263,600$3,637,680→ 2,458,445 total(indirect: See footnotes) - Sale
Common Stock
2020-04-03$13.80/sh−36,400$502,320→ 339,480 total(indirect: See footnotes) - Sale
Common Stock
2020-04-07$14.20/sh−5,373$76,297→ 2,453,072 total(indirect: See footnotes) - Sale
Common Stock
2020-04-07$14.20/sh−742$10,536→ 338,738 total(indirect: See footnotes)
Vivo Capital Surplus Fund VIII, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-04-03$13.80/sh−263,600$3,637,680→ 2,458,445 total(indirect: See footnotes) - Sale
Common Stock
2020-04-03$13.80/sh−36,400$502,320→ 339,480 total(indirect: See footnotes) - Sale
Common Stock
2020-04-07$14.20/sh−742$10,536→ 338,738 total(indirect: See footnotes) - Sale
Common Stock
2020-04-07$14.20/sh−5,373$76,297→ 2,453,072 total(indirect: See footnotes)
Footnotes (4)
- [F1]These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").
- [F2]These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").
- [F3]Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
- [F4]The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0 to $15.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
Documents
Issuer
Crinetics Pharmaceuticals, Inc.
CIK 0001658247
Entity typeother
Related Parties
1- filerCIK 0001628048
Filing Metadata
- Form type
- 4
- Filed
- Apr 6, 8:00 PM ET
- Accepted
- Apr 7, 7:27 PM ET
- Size
- 14.8 KB